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doi:10.1Objective: In patients with hypertrophic cardiomyopathy with bifid hypermobile papillary muscles and a dy-
namic left ventricular outflow tract gradient, we performed surgical papillary muscle reorientation, fixing the mo-
bile papillary muscle to the posterior left ventricle to reduce mobility. We report the outcomes of patients with
hypertrophic cardiomyopathy undergoing surgical papillary muscle reorientation versus those of patients under-
going standard surgical procedures.
Methods:We studied 204 consecutive patients with hypertrophic cardiomyopathy undergoing surgical interven-
tion (after consensus decision) for symptomatic left ventricular outflow tract gradient. Preoperative and postop-
erative maximal (resting/provocable) left ventricular outflow tract gradients were recorded by using
echocardiographic analysis.
Results: The population was divided into 3 groups: (1) isolated myectomy (n ¼ 143; age, 54  14 years; 48%
men), (2) myectomy plus mitral valve repair/replacement (n ¼ 39; age, 54  13 years; 54% men), and (3) pap-
illary muscle reorientation with or without myectomy (n ¼ 22; age, 50  14 years; 59% men). The mean pre-
operative (103  32, 103  32, and 114  36 mm Hg; P ¼ .3) and predischarge (15  18, 14  14, and 16
 21 mm Hg; P ¼ .9) maximal left ventricular outflow tract gradients were similar. There were no deaths either
in the hospital or at 30 days. At a median follow-up of 166 days (interquartile range, 74–343 days), 21 of 22
patients in group 3 were asymptomatic. One patient in group 3 had a symptomatic left ventricular outflow tract
gradient (87 mm Hg) requiring mitral valve replacement.
Conclusions: In patients with hypertrophic cardiomyopathy with bifid hypermobile papillary muscles (even with
a basal septal thickness<1.5 cm), papillary muscle reorientation reduces the symptomatic left ventricular outflow
tract gradient. Long-term outcomes need to be ascertained. (J Thorac Cardiovasc Surg 2010;140:317-24)Video clip is available online.Hypertrophic cardiomyopathy (HCM) is a complex disorder
with a broad phenotypic expression and varied clinical out-
comes. The most common morphologic form involves basal
interventricular septal hypertrophy and concomitant systolic
anterior motion (SAM) of the anterior mitral valve leaflet, re-
sulting in dynamic left ventricular outflow tract (LVOT) ob-
struction (Figure 1, A).1,2 The degree of dynamic LVOTe Tomsich Department of Cardiovascular Medicinea and Department of
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The Journal of Thoracic and Caobstruction has prognostic significance.3 Therefore surgical
and percutaneous treatments have traditionally focused on
surgically removing or percutaneously ablating (with alco-
hol) part of the basal interventricular septum, with excellent
long-term outcomes.4-8 However, multiple previous studies
have cited other concomitant contributors to dynamic
LVOT obstruction, particularly mitral leaflet and subvalvar
pathology (Figure 1, B and C).9-12 As a result, surgical tech-
niques that combine extensivemyectomywith or without mi-
tral valve surgery have evolved over time, with excellent
outcomes.13However, dynamicLVOTobstruction is increas-
ingly recognized in patients with HCM with minimal or no
basal septal hypertrophy (Figure 1, D).14,15 In some patients
with LVOTobstruction, abnormal papillarymusclemorphol-
ogy, including anteroapical displacement and bifid papillary
muscles, has been frequently observed.10,16 In a recent study
we demonstrated that abnormal papillarymusclemorphology
was associatedwith dynamicLVOTobstruction, independent
of basal septal thickness.10 We have noticed that a subset of
patients with dynamic LVOT obstruction have bifid and hy-
permobile papillary muscles, such that they potentially added
to the obstructive physiology, even without significant basal
septal hypertrophy. To optimally reduce/abolish dynamicrdiovascular Surgery c Volume 140, Number 2 317
Abbreviations and Acronyms
CMR ¼ cardiac magnetic resonance
HCM ¼ hypertrophic cardiomyopathy
LVOT ¼ left ventricular outflow tract
SAM ¼ systolic anterior motion
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DLVOTobstruction in suchpatients,wehaveadapteda surgical
approach to reorient the papillary muscles away from the
LVOT (with or without myectomy).15,17 We report the base-
line characteristics and short-term outcomes of patients with
HCM who underwent papillary muscle reorientation while
comparing them with patients who underwent standard
surgical approaches (myectomy with or without mitral valve
surgery) for relief of dynamic LVOT obstruction.MATERIALS AND METHODS
Between January 2007 and July 2008, 237 patients with HCM were re-
ferred for surgical intervention for LVOT obstruction after undergoing
a comprehensive clinical, electrocardiographic, and multimodality imaging
evaluation. All patients were referred for surgical intervention only after
consensus between cardiologists and cardiothoracic surgeons experienced
in the management of HCM. HCMwas defined as a hypertrophied and non-
dilated left ventricle in the absence of another cardiac or systemic disease
that could result in a similar magnitude of hypertrophy.1,2 Of these 237 pa-
tients, 33 also had concomitant significant aortic valve disease, subaortic
membrane, or both, necessitating complex procedures in addition to myec-
tomy (including aortic valve replacement, membrane resection, or both).
These patients were excluded from the current analysis. Hence the final
study population consisted of 204 patients who underwent surgical interven-
tion for symptomatic, dynamic LVOT obstruction. All patients had intrac-
table symptoms despite taking medications at maximum tolerable
dosages. Baseline demographic, clinical, and medication data, along with
postoperative clinical data, were obtained from an institutional database
(an ongoing institutional review board–approved registry). In addition, for
the group of patients who underwent papillary muscle reorientation (group
3, as described below), assessment of symptoms in the postoperative period
was ascertained by means of a telephone call, outpatient clinic visit, or both.
The Social Security Death Index was queried to determine survival for all
patients. When possible, cause of death was ascertained.
Imaging Protocol
Baseline and postoperative (predischarge) surface echocardiograms
were performed with commercially available instruments (HDI 5000; Phi-
lips Medical Systems, N.A., Bothell, Wash and Acuson Sequoia; Siemens
Medical Solution USA, Inc, Malvern, Pa) as part of standard clinical prac-
tice. Basal interventricular septal thickness was recorded according to
American Society of Echocardiography recommendations.18 Left ventricu-
lar outflow peak velocity was measured by means of continuous-wave
Doppler echocardiography, and LVOT pressure gradient was estimated
by using the simplified Bernoulli equation.19 Care was taken to avoid con-
tamination of the LVOT waveform by the mitral regurgitation jet.3 In pa-
tients with resting LVOT gradients of less than 30 mm Hg, provocative
maneuvers, including Valsalva and amyl nitrite, were used. In 160 patients
with resting LVOT gradients of less than 100 mm Hg, exercise echocardio-
graphic analysis was performed, as previously described.20 Maximal resting
gradient was defined as the maximum (either resting, provoked, or after ex-
ercise) LVOT gradient in a given patient. The degree of resting mitral regur-318 The Journal of Thoracic and Cardiovascular Surggitation was assessed by means of color Doppler scanning. After
incorporation of jet width, volume, flow convergence,21 and left atrial
size, a composite grade of 0 to 4þ (0, none; 0.5, trivial; 1þ, mild; 2þ, mod-
erate; 3þ, moderately severe; and 4þ, severe) was assigned to each patient.
Also, the direction of the mitral regurgitant jet was noted in each patient.
A characteristic posteriorly directed mitral regurgitant jet with associated
SAM was deemed to be due to dynamic LVOT obstruction. On the other
hand, the patient was categorized as having intrinsic mitral valvular pathol-
ogy if the leaflets were abnormally thickened, calcified, or elongated; had
restricted mobility; and had a concomitant central or anteriorly directed jet.
All patients undergoing surgical intervention underwent intraoperative
transesophageal echocardiographic analysis in a standard fashion.22 In addi-
tion, patients underwent standard postoperative surface echocardiographic
analysis before discharge, as described above, including assessment of rest-
ing and provocable (Valsalva and amyl nitrite) maneuvers. Stress echocar-
diographic analysis was not performed postoperatively.
Also, 122 patients (without standard contraindications, including pace-
maker, implantable cardioverter defibrillators, aneurysm clips, significant
arrhythmias, or severe claustrophobia) underwent a comprehensive electro-
cardiographically gated cardiac magnetic resonance (CMR) examination on
1.5 T scanner (Siemens Avanto; SiemensMedical Solutions, Erlangen, Ger-
many) to assess left ventricular morphology, as previously described.10
During echocardiographic and CMR examinations, special attention
was given to papillary muscle morphology (including the number of heads,
abnormal attachment to the anterior mitral leaflet, the presence of bifid
muscles, and hypermobility of the muscle heads), along with their contri-
bution to dynamic LVOT obstruction (see Videos 1 and 2). Papillary mus-
cles were deemed hypermobile based on the presence of all of the following
criteria: (1) excessive motion, (2) close proximity of the papillary muscle to
the interventricular septum in late systole, and (3) the presence of concom-
itant SAM of the mitral valve. We recorded provocable SAM and LVOT
obstruction, even in the absence of significant basal septal hypertrophy
(Figure 2). Because there is no previously described objective method to
define the hypermobility of papillary muscles, it was a consensus definition
after discussion between the cardiologists and cardiothoracic surgeons.Surgical Technique
The type of operation was decided based on expert consensus after thor-
ough evaluation between cardiologists and cardiothoracic surgeons experi-
enced in managing patients with HCM, taking into account the findings on
preoperative imaging evaluation and intraoperative findings (HML, BWL,
NGS, MT, and MYD). In our surgeons’ experience of multiple hundreds
of myectomies over the last more than 10 years, they have found the trans-
aortic approach much easier compared with the transatrial approach. Hence
all procedures were performed with the transaortic approach. Specific issues
taken into consideration included basal septal thickness andmitral valve and
papillary muscle morphology. The patients were divided into the following
groups based on the surgical techniques used: (1) isolated myectomy (n ¼
143), (2) myectomy plus mitral valve repair/replacement (n ¼ 39), and (3)
papillary muscle reorientation with or without myectomy (n¼ 22). The de-
tails of the first 2 techniques have been described previously.8,13
To perform surgical reorientation (group 3), papillary muscles had to be
deemed bifid and hypermobile on multimodality imaging (including intra-
operative transesophageal echocardiographic analysis), with the final deci-
sion made on intraoperative visualization by the surgeon. The papillary
muscle realignment procedure was performed through the aortic valve. A
pledgeted mattress suture was placed posterior to the most posterior papil-
lary muscle head, avoiding entanglement with the chordae. It was then
passed through the anterior head, avoiding twisting of the papillary muscle
(Figure 3 and see Video 3). The sutures were passed through the fibrous por-
tion to avoid ischemia of the papillary muscle. One or more mattress sutures
were used to realign the papillarymuscles, and both anterolateral and poster-
omedial papillary muscles have been realigned as deemed necessary.17 The
degree to which the sutures were tightened was subjectively decided by theery c August 2010
FIGURE 1. Schematic representation of different phenotypic presentations of dynamic left ventricular outflow tract obstruction in patients with hypertrophic
cardiomyopathy. A, Typical basal septal hypertrophy resulting in systolic anterior motion of the mitral valve and outflow tract obstruction. B, Abnormal an-
terior leaflet of the mitral valve in addition to basal septal hypertrophy, resulting in systolic anterior motion of the mitral valve and outflow tract obstruction. C,
Hypermobile bifid papillary muscles, along with basal septal hypertrophy, resulting in systolic anterior motion of the mitral valve and outflow tract obstruc-
tion. D, Hypermobile bifid papillary muscles without basal septal hypertrophy, resulting in systolic anterior motion of mitral valve and outflow tract obstruc-
tion. IVS, Interventricular septum; Ao, aorta; LA, left atrium; PM, papillary muscles; MV, mitral valve.
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mobility, hence relieving the LVOT obstruction, which was confirmed in-
traoperatively with an isoproterenol challenge.
Statistical Analysis
Baseline demographics, risk factors, and clinical variables are descrip-
tively summarized for the group. Continuous variables are expressed as
means standard deviations or medians with interquartile ranges. Categor-
ical data are presented as percentage frequencies. Differences between theFIGURE 2. Apical long-axis view in the patient (as in Videos 1–3) without
significant basal septal hypertrophy demonstrating the characteristic late-
peaking Doppler profile across the left ventricular outflow tract, suggesting
dynamic obstruction.
The Journal of Thoracic and Cagroups were compared by using the Student’s t test or analysis of variance
for continuous variables (Mann–Whitney test for nonparametric variables,
where appropriate) and the c2 test for categorical variables. Data assembly
and basic statistical comparisons were performed with JMP Software ver-
sion 6.0.2. Advanced statistical analysis was performed with Statistica ver-
sion 6.1 (Statsoft, Tulsa, Okla).RESULTS
Baseline clinical and demographic criteria for all the
groups are shown in Table 1. There were no significant dif-
ferences in age, sex, and standard clinical risk factors be-
tween the different groups. However, as might be
expected, patients with concomitant mitral valvular pathol-
ogy had increased severity of mitral regurgitation and fre-
quency of atrial fibrillation. Thirteen patients in group 1
had advanced conduction disease at baseline (including 6
with right bundle branch block, 3 with bifascicular block,
and 4 with left bundle branch block). No patients in the other
groups had conduction disease at baseline.Baseline Echocardiographic Data
Within the study population, all patients had a preopera-
tive resting surface echocardiogram and an intraoperative
transesophageal echocardiogram. Eighty-two patients in
group 1, 25 in group 2, and 15 in group 3 had a preoperative
CMR evaluation. The preoperative echocardiographic data
are shown in Table 2. All patients had a preserved leftrdiovascular Surgery c Volume 140, Number 2 319
FIGURE 3. Schematic representation demonstrating reorientation of abnormal bifid papillary muscles away from the left ventricular outflow tract. In this
demonstration both anterolateral and posteromedial papillary muscles are realigned, abolishing the outflow tract gradient. IVS, Interventricular septum; LA,
left atrium.
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Dventricular ejection fraction, with no difference between
groups. All patients had a maximal (either resting or provo-
cable) LVOT gradient of greater than 50 mm Hg on Doppler
echocardiographic analysis. There was no significant differ-
ence in the maximal LVOT gradient between the groups.
The mean basal septal thickness was similar in the first 2
groups; however, it was significantly lower in group 3. All
patients in group 2 were deemed to have intrinsic mitral
valve pathology in addition to SAM of the mitral valve.
On multimodality imaging evaluation, all patients in group
3 had hypermobile and bifid papillary muscles, which
were thought, by a consensus opinion of at least 2 authors,
to aid in dynamic LVOT obstruction.
In group 3 there were 11 patients (mean age, 49  18
years; 73% men) with a maximal basal septal thickness of
less than 1.5 cm. All these patients were symptomatic
(100% with New York Heart Association [NYHA] class
>II), and 10 of 11 were taking b-blockers. The maximal
LVOT gradient was similar to those of the other groups
(124  36 mm Hg).TABLE 1. Baseline clinical characteristics of the study population
Group 1, myectomy
(n ¼ 143)
Group 2
Age (y) 54  14
Male sex 69 (48%)
Hypertension 76 (53%)
Diabetes mellitus 15 (10%)
Stroke 3 (2%)
Smoking 51 (36%)
Atrial fibrillation 7 (5%)
Permanent pacemaker 3 (2%)
Syncope 35 (24%)
b-Blocker 118 (83%)
New York Heart Association class III 197 (95%)
Body mass index (kg/m2) 26  5
Serum creatinine (mg/dL) 0.97  0.2
MV, Mitral valve; PMR, papillary muscle reorientation.
320 The Journal of Thoracic and Cardiovascular SurgPerioperative Data
There were no intraoperative deaths in the study popula-
tion. There was 0% in-hospital or 30-day mortality. There
was no difference between the treatment groups in terms
of hospital admission days, intensive care unit length of
stay, or postoperative complications. There was no differ-
ence in postsurgical LVOT gradients or degree of mitral re-
gurgitation between the treatment groups. Also, of the 16
patients with new pacemaker-dependent complete heart
block, 10 had pre-existing advanced conduction disease.
None of the patients who underwent papillary muscle reor-
ientation in group 3 had conduction abnormalities necessi-
tating permanent pacemaker implantation. The clinical
perioperative data, divided into different groups, is shown
in Table 3.
Follow-up Data
As shown in Table 3, there were no intraoperative or in-
hospital deaths. During a median follow-up (for survival)
of 311 days (interquartile range, 150–458 days), there, myectomyþMV surgery
(n ¼ 39)
Group 3, PMR ± myectomy
(n ¼ 22)
P
value
54  13 50  14 .4
21 (54%) 16 (73%) .09
24 (62%) 13 (59%) .6
8 (21%) 1 (5%) .1
1 (3%) 1 (5%) .8
14 (36%) 4 (18%) .8
7 (18%) 0 (0%) .009
6 (15%) 4 (18%) .8
6 (15%) 4 (18%) .4
31 (79%) 15 (68%) .3
38 (97%) 21 (95%) .8
27  6 27  6 .6
0.99  0.2 0.96  0.2 .9
ery c August 2010
TABLE 2. Baseline echocardiographic characteristics of the study population
Group 1 Group 2 Group 3 P value
Maximal end-diastolic basal septal thickness (cm) 2.17  0.5 2.01  0.4 1.66  0.4 <.001
Maximal end-diastolic posterior wall thickness (cm) 1.38  0.3 1.39  0.3 1.23  0.2 .07
Left ventricular ejection fraction (%) 63  5 62  6 61  5 .2
Degree of resting mitral regurgitation, mean  SD;
median (interquartile range)
1.8  1.0; 2 (1–3) 1.9  1.3; 2 (1–3) 1.3  0.8; 1 (0.5–2) .07
Baseline resting peak LVOT gradient (mm Hg),
mean  SD; median (interquartile range)
62  42; 58 (24–98) 65  47; 57 (17–105) 41  41; 33 (11–64) .08
Baseline maximal (either resting or provocable)
peak LVOT gradient (mm Hg),
mean  SD; median (interquartile range)
103  32; 100 (85–119) 103  32; 100 (81–120) 114  36; 116 (87–133) .3
The groups are those described in Table 1. SD, Standard deviation; LVOT, left ventricular outflow tract.
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occurred in a 71-year-old woman in group 1 (postoperative
day 48), and the cause of death is unknown. The second
death occurred in a 52-year-old woman in group 2 and
was caused by a pulmonary embolism (postoperative day
47). There have been no deaths in group 3.
In addition, we made follow-up telephone calls to all pa-
tients in group 3. At a mean follow-up of 224 days (median,
166 days; interquartile range, 74–343 days), 21 of 22 pa-
tients were in functional class I with no functional limitation
and were free from reoperation. Only 1 patient in group 3
who underwent papillary muscle reorientation only (a 53-
year-old man; preoperative basal septal thickness, 1.5 cm;
maximal baseline LVOT gradient, 132 mm Hg) had a recur-
rent provocable LVOT gradient at the 3-month follow-up
(87 mm Hg), in addition to moderately severe mitral regur-
gitation, SAM, and progression to NYHA class III symp-
toms. This patient subsequently underwent mitral valve
replacement and is currently symptom free and alive.TABLE 3. Perioperative and postoperative characteristics of the study po
Group 1
Concomitant coronary artery bypass surgery 22 (15%)
Admission days during operation 8  5
Intensive care unit days 1.6  1.3
Myocardial infarction 0
Bleeding 4 (3%)
Stroke 0
Renal failure 0
New permanent pacemaker 13 (9%)
New left bundle branch block 143 (100%)
Resting peak LVOT gradient (mm Hg), mean  SD;
median (interquartile range)
10  10; 10 (0–16
Maximal (Valsalva or amyl nitrite) peak LVOT
gradient (mm Hg), mean  SD; median
(interquartile range)
15  18; 12 (0–22
Postoperative mitral regurgitation, mean  SD;
median (interquartile range)
0.5  0.5; 0.5 (0.5–0
Reoperation during follow-up 0
30-d Mortality 0
The groups are those described in Table 1. SD, Standard deviation; LVOT, left ventricular
The Journal of Thoracic and CaFrom group 3, 11 other patients have returned for follow-
up clinic visits and echocardiograms. The average resting
and maximal LVOT gradients were 9  8 and 10  10
mm Hg, respectively. All these patients had trivial mitral re-
gurgitation and no evidence of SAM.
DISCUSSION
This study is the first to report characteristics and short-
term outcomes in a series of patients with HCM with symp-
tomatic dynamic LVOT obstruction despite maximal medi-
cal therapy who underwent papillary muscle reorientation
with or without myectomy. The baseline characteristics
were similar (except for lesser frequency of atrial fibrilla-
tion) to those of the typical symptomatic population of pa-
tients with HCM who underwent myectomy with or
without mitral valve surgery. Although the degree of provo-
cable LVOT gradient was similar, the patients in group 3 had
a significantly thinner basal septum; in fact, there were 11
patients with a basal septal thickness of less than 1.5 cm.pulation
Group 2 Group 3 P value
2 (5%) 1 (5%) .1
8  6 6  2 .3
1.6  1.4 1.6  1 .9
0 0
0 1 (5%) .3
0 0
0 0
3 (8%) 0 .1
39 (100%) 16 (73%) <.01
) 9  9; 8 (0–18) 9  9; 9 (0–16) .8
) 14  14; 14 (0–26) 16  21; 11 (0–18) .9
.5) 0.5  0.4; 0.5 (0.5–0.5) 0.4  0.3; 0.5 (0.5–0.5) .3
0 1
0 0
outflow tract.
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technique, with no in-hospital or 30-day mortality and a sim-
ilar rate of perioperative complications compared with stan-
dard techniques. On predischarge echocardiographic
analysis, all patients had successful relief of resting and pro-
vocable LVOT obstruction. Furthermore, there was signifi-
cant reduction of the degree of mitral regurgitation to
a similar extent in all groups. No patient in the papillary mus-
cle reorientation group required a permanent pacemaker in
the postoperative setting.
At short-term follow-up, all patients in group 3 (except for
1 patient) were asymptomatic and without a need for reoper-
ation. Only 1 patient presented with persistent symptoms
and increased LVOT gradient after undergoing papillary
muscle reorientation during follow-up. This patient was
one of the initial patients who underwent isolated papillary
muscle reorientation and was symptom free at discharge.
However, he presented with a sudden worsening shortness
of breath 2 months after his operation and was found to
have an increased LVOT gradient and SAM, requiring sur-
gical reintervention. Intraoperatively, the sutures on the pos-
terior aspect of the bifid anterolateral muscle had dislodged,
resulting in resumption of the laxity in the anterolateral pap-
illary muscle. Although we could have replaced the suture, it
was a clinical decision not to do so because the patient was
relatively young and we did not want to subject him to an-
other operation should simple resuturing have failed again.
This patient subsequently underwent mitral valve replace-
ment and recovered normally, is currently alive, and is
asymptomatic. We do not report the short- and long-term
outcomes data of groups 1 to 3 because they have been pre-
viously published.8,13
Dynamic LVOT obstruction is responsible for a sizable
proportion of symptoms associated with HCM. An increased
LVOT gradient carries prognostic significance in patients
with HCM,23 and such patients with a resting gradient of
30 mm Hg or greater had a 4-fold increased risk of death
or progression to severe congestive symptoms compared
with those without obstruction.3 Furthermore, the resolution
of LVOT gradient has been demonstrated to improve sur-
vival.3,6 An increase in the size of the LVOT is traditionally
achieved through surgical myectomy (with or without mitral
valve surgery) or alcohol septal ablation, with excellent out-
comes.4–8
However, recent studies with high-resolution 3-dimen-
sional CMR have demonstrated a high frequency of papil-
lary muscle abnormalities (anteroapical displacement,
double bifid papillary muscles, or both) in patients with
HCM, which are frequently missed on echocardiographic
analysis.10,16 In the study by Kwon and colleagues,10 the
odds of having an abnormal resting LVOT gradient were
significantly higher in those patients with HCM who also
had abnormal papillary muscles, independent of septal
thickness.322 The Journal of Thoracic and Cardiovascular SurgPrevious studies have also demonstrated the effect of al-
tered papillary muscle morphology in dogs. This study re-
produced SAM in dogs with structurally normal hearts and
mitral valves by anteriorly displacing the papillary muscles
through a suture mechanism.24 SAM in these dogs was a re-
sult of the decrease in effective posterior restraint (increased
leaflet slack) caused by anterior redirection of papillary mus-
cle tension, increased length of the residual leaflet, and coap-
tation of the mitral valve leaflets in LVOT, subjecting the
leaflets to drag forces25 that propel the leaflet anteriorly.
The anteriorly displaced leaflets are more likely pushed
into the LVOT by drag forces, as opposed to the Venturi ef-
fect, because the onset of SAM occurs when the velocity in
the LVOT is normal or low.
Clinical Implications
In our clinical practice we have seen multiple patients
with dynamic LVOT obstruction in the setting of minimal
or no basal septal hypertrophy. It is not clear whether this
represents an earlier stage of the HCM disease process be-
fore the development of characteristic basal septal hypertro-
phy. In a recent case report, we described a highly
symptomatic 18-year-old patient with normal septal thick-
ness and a significant LVOT gradient. This patient was
noted to have multiple hypermobile papillary muscles heads
that obstructed the LVOT during systole. This patient was
gene positive for HCM. The LVOT obstruction was effec-
tively eliminated by means of papillary muscle reorientation
alone without myectomy.15 As one might recognize, this
subgroup of patients with HCM presents a surgical dilemma
if medical therapy fails because the basal septum is not
‘‘thick enough’’ to contribute to LVOT obstruction. There-
fore performing extensive myectomy in such patients would
only put them at risk for iatrogenic ventricular septal defect
without effectively alleviating of the obstruction. Perform-
ing mitral valve repair (including an Alfieri stitch) would
also not be appropriate in such patients. Similarly, perform-
ing alcohol septal ablation would also not be of any clinical
utility.
In our experience reorientation of 1 or more papillary
muscle heads away from the LVOT effectively and safely re-
lieves obstruction while concomitantly preserving mitral
valve function. Also, because in most cases this can be
achieved by no myectomy (or at most a minimyectomy of
<5 mm), potential injury to the conduction system and pace-
maker dependence could also be less of a concern. However,
this needs to be validated with longer-term follow-up.
Thus at our institution, we use the following pathway for
management of patients with dynamic LVOT obstructions
and intractable symptoms. The first step is to establish the
morphologic basis of dynamic LVOT obstruction with mul-
timodality imaging: basal septal hypertrophy versus mitral
pathology versus papillary muscle hypermobility. The vast
majority of patients with dynamic LVOT obstruction haveery c August 2010
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extensive myectomy. A smaller proportion of patients with
dynamic LVOT obstruction have concomitant mitral valve
pathology that needs to be addressed at the time of myec-
tomy to yield optimal results. There is another small group
of patients who have an obvious symptomatic dynamic
LVOT obstruction without significant basal septal hypertro-
phy. These patients need to be further evaluated for 2 scenar-
ios, isolated intrinsic mitral valve pathology or bifid/apically
displaced papillary muscle that is hypermobile. In the first
scenario mitral valve repair/replacement is the optimal ap-
proach, and in the second scenario (hitherto underrecog-
nized) we approach it using papillary muscle reorientation.
Of course, there have been a few patients in whom we
have performed all 3 procedures for optimal relief of ob-
struction.
Limitations and Future Outlook
We acknowledge the following limitations of our study.
The study was conducted at a tertiary referral center with
a significant selection bias. The patients in our study had sig-
nificant symptoms and were therefore referred to our center
for a cardiac evaluation. Assessment of papillary muscle
morphology by means of multimodality imaging is not stan-
dardized, and at present, it is subjective based on visual as-
sessment. One might argue that the papillary muscle
reorientation (in addition to myectomy) might not have
been necessary, particularly in patients of group 3, who al-
ready had a relatively thick basal septum. However, a deci-
sion regarding the choice of operative approach in this group
was made based on expert consensus after detailed multimo-
dality imaging evaluation and an understanding that myec-
tomy alone would be insufficient, whereas mitral valve
surgery would remain unindicated. Certainly, extensive
myectomy was not an option in group 3 patients with the
basal septum measured at less than 1.5 cm.
Dedicated multimodality imaging protocols that objec-
tively detail papillary muscle morphology (especially with
CMR) need to be established and validated prospectively.
In the current study CMR was not uniformly performed in
all patients because of various contraindications (most com-
mon being a pacemaker/defibrillator), as outlined before.
Also, although papillary muscle reorientation is a relatively
simple surgical technique, expertise after an obligatory
learning curve would need to be developed. Finally, lon-
ger-term follow-up is needed to compare outcomes (includ-
ing freedom from reoperation) for papillary muscle
reorientation with or without surgical myectomy vs myec-
tomy alone in a more comprehensive manner.
CONCLUSIONS
In a subset of patients with HCM who have bifid, hyper-
mobile papillary muscles (with or without basal interventric-
ular septal hypertrophy), papillary muscle reorientationThe Journal of Thoracic and Caeffectively reduces LVOT obstruction, without a need for
mitral valve replacement. Although short-term outcomes
(including freedom from reoperation) are good, long-term
outcomes need to be ascertained.References
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